logo

UNCY

Unicycive
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
Consensus Rating "Strong Buy"
EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About UNCY

Unicycive Therapeutics, Inc.

A biotech company that develops novel treatments for kidney diseases

Biological Technology
08/18/2016
07/13/2021
NASDAQ Stock Exchange
22
12-31
Common stock
4300 El Camino Real, Suite 210, Los Altos, CA 94022
--
Unicycive Therapeutics, Inc., was incorporated in Delaware on August 18, 2016. The company was dormant until July 2017 when it began evaluating some drug candidates for licensing. The company is a biotechnology company that develops treatments for certain medical conditions. Currently, the company's two projects focus on kidney disease. As the company grows and the team is built, the company intends to focus on identifying medical conditions inside and outside kidney disease. The company's current development programs focus on two new therapies: cyanide carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis, and UNI 494 for the treatment of acute kidney injury (AKI).

Company Financials

EPS

UNCY has released its 2025 Q1 earnings. EPS was reported at -0.05, versus the expected -0.06, beating expectations. The chart below visualizes how UNCY has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime